Overview

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborators:
Cardiome Pharma
Correvio International Sarl